BRAF and neoplasm: In a study comparing KRAS and BRAF mutations in both metastatic CRC plasma cfDNA and tumour tissue, specificity and sensitivity of 100% for BRAF V600E mutation and 96% on KRAS point mutations have been demonstrated.